Coagulation balance is maintained through fine-tuning interactions among clotting factors. 
Introduction
Normal coagulation pathway represents a balance between pro-coagulant and anti-coagulant pathway through fine-tuning interactions among clotting factors (Adams and Bird, 2009; Davie et al., 1991; Esmon, 1989 Esmon, , 2000 Palta et al., 2014; Smith et al., 2015) . Nineteen clotting factors have been identified to take part in the coagulation cascade and to maintain the thrombohemorrhagic balance (Esmon, 2000; Jesty and Beltrami, 2005; Palta et al., 2014; PerezGomez and Bover, 2007) . They include fibrinogen family (fibrinogen (factor I), factor V, factor VIII and factor XIII) (Triplett, 2000) , vitamin K dependent family ((factor II, thrombin), factor VII, factor IX and factor X) (Bhattacharyya et al., 2005; Mann et al., 1990) , contact family (factor XI, factor XII, high molecular weight kininogen (HMWK, factor XV) and prekallikerin (PK, factor XIV)) (Schmaier, 2016; Travers et al., 2015) , tissue factor (factor III), calcium (factor IV), Von Willebrand factor (vWf, factor XVI), antithrombin III (AT-III, factor XVII), heparin cofactor-II (factor XVIII), protein C (factor XIX) and protein S (factor XX) (Davie, 2003; Newland, 1987; Palta et al., 2014; Periayah et al., 2017; Schmaier, 2016) . They are resembled a coagulation waterfall or cascade comprising of the intrinsic and the extrinsic pathways, which converge in FX activation (Davie, 2003; Hoffman, 2003; Hougie, 2004) . In this model, each clotting factor consists of a proenzyme that is converted to an active enzyme by the upstream activated clotting factor (Furie and Furie, 1988) . Normally, the coagulation process is under the inhibitory control of several inhibitors to create a physiological balance between anticoagulant and antifibrinolytic pathways, which is named coagulation balance to avoid too much and too little clot production (Chan and Paredes, 2013; Esmon, 1989; Ganter and Spahn, 2010; Mann et al., 2009; Palta et al., 2014; Roderique and Wynands, 1967) .
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Fine-tuning interactions among clotting factors play key roles for maintaining coagulation balance but the concentration of clotting factors is huge difference (Palta et al., 2014) . Normally, the concentration of fibrinogen, prothrombin, and AT-III is ~10, ~2 and ~3 M, respectively, while that for most of coagulation proteases is pM to nM (Esmon, 2000) . AT-III is the main natural inactivator of coagulation proteases to limit the clot formation, thus avoiding the thrombus propagation (Esmon, 2000) . Given the huge concentration difference of different clotting factors, especially that the concentration of coagulation proteases is thousands times lower that of their physiological inactivator AT-III, we suppose that there are some adjusters or balancers to orchestrate or buffer imbalanced clotting factors with different concentration, or to sequester interactive objects in normal plasma. We found that transferrin (Tf), an endogenous plasma protein with high concentration of 40 M that transports iron (Gkouvatsos et al., 2012; Prinsen et al., 2001) , acts as a clotting factor and an adjuster for maintaining coagulation balance by interacting with not only clotting factors with high concentration, i.e., fibrinogen and AT-III, but also clotting factors with low concentration, i.e., coagulation proteases. Usually, most of Tf is sequestered from coagulation proteases and AT-III by binding with fibrinogen.
Results

Enhanced enzymatic activity of thrombin and FXIIa is associated with elevated Tf in atherosclerosis
In order to investigate the mechanism responsible for atherosclerosis (AS)-associated hypercoagulability, enzymatic activities of several coagulation factors including FVIIa, FXIa, FXIIa, kallikrein and thrombin were compared between plasma from healthy people and atherosclerotic patients (coronary heart disease (CHD) patients) who had angiographicallyPage | 6 visible luminal narrowing (Table S1 ). The enzymatic activity of thrombin and FXIIa in atherosclerotic plasma was found to be 2-2.5 times stronger than that in healthy plasma ( Figure   S1A ), although total levels of prothrombin and FXII are not different (Figures S1B-S1D), suggesting the presence of factors potentiating the activation or activities of thrombin/FXIIa in atherosclerotic plasma. The enzymatic activity of kallikrein, FXIa and FVIIa are not significantly different between plasmas from AS patients and normal controls ( Figure S1A ). The factor with potentiating effects on thrombin/FXIIa was purified and identified as Tf ( Figures S2 ). An anti-Tf antibody (Tf AB) blocked the elevation of the enzymatic activities of thrombin ( Figure 1A ) and FXIIa ( Figure 1B ) in the atherosclerotic plasma, further suggesting that Tf is a potentiator for these two coagulation factors. Comparative analysis using enzyme linked immunosorbent assay (ELISA) and western blot confirmed that there are elevated Tf in atherosclerotic plasma (Figures S1C and S1D). The average Tf concentration in the plasma of CHD patients (n = 42, male 22; female 20) was 4.173 mg/ml (SD 1.19), while that in healthy individuals (n = 42, male 21; female 21) was 2.865 mg/ml (SD 0.33) ( Figure 1C ). High levels of Tf were also observed in the atherosclerotic lesion specimens ( Figure 1E and Table S2 ).
To further investigate the association of elevated Tf with atherosclerosis, the Apoe -/-mice were fed a normal diet (ND) or a high fat diet (HFD, 21% fat, 0.15% cholesterol) for 6 weeks to test the change of Tf in the plasma and atherosclerotic plaque. Notably, elevated Tf level was observed in the plasma of HFD fed Apoe -/-mice ( Figure 1F ), which was congruent with atherosclerotic plaque development ( Figure S3A ). Confocal microscopy and immunoblot analysis also showed increased Tf in atherosclerotic plaque (Figures 1G and 1H) . In addition, quantitative real-time polymerase chain reaction (qRT-PCR) showed the Tf RNA is dominantly up-regulated in liver, indicating that liver is the main site of Tf synthesis ( Figure S3B ).
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Tf potentiates thrombin/FXIIa and inhibits AT-III independently of iron
As an iron carrier, Tf exists in plasma in both the ferric iron-bound state (holo-Tf) or unbound state (apo-Tf). As illustrated in Figures 2A and 2D , both apo-Tf and holo-Tf were found to show a similar effect to enhance the enzymatic activities of thrombin and FXIIa. At the concentration of 0.2, 1 and 5 M, Tf enhanced the enzymatic activity of thrombin by 0.2, 1 and 1.8-fold, while that for FXIIa was 0.2, 0.7 and 1.5-fold, respectively. Similarly, apo-Tf and holo-Tf exhibited no difference in promoting coagulation through shortening the recalcification time ( Figure S4 ). 2C ). At the concentration of 0.2, 1 and 5 μM, Tf increased the ability of FXIIa to release the hydrolytic product (kallikrein heavy chain (HC), 52 kDa) of PK by 0.8, 1.9 and 2.7-fold, respectively (Figures 2E and 2F) . Tf showed effects on neither zymogen activation of thrombin and FXIIa nor activities of kallikrein, FXIa and FVIIa ( Figure S5 ). As illustrated in Figures 2G and 2I , both apo-Tf and holo-Tf blocked the inhibitory activity of AT-III towards thrombin and FXa. The inactivation on thrombin and FXa by 2 M AT-III was completed blocked by 10 M Tf. As a result, generation of thrombin-AT-III (TAT) and FXa-AT-III complexes were blocked ( Figures   2H and 2J ). In addition, thrombin-induced platelet aggregation was augmented by Tf ( Figure S6 ).
These data indicate that Tf induces hypercoagulability by potentiating thrombin and FXIIa and blocking inactivation of antithrombin III on thrombin and FXa.
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Tf directly interacts with thrombin, FXIIa, fibrinogen and AT-III
Surface plasmon resonance (SPR) analysis revealed that apo-Tf directly interacts with thrombin ( Figure 3A ), FXIIa ( Figure 3B ), fibrinogen ( Figure 3C ) and AT-III ( Figure 3D ), whereas human serum albumin (HSA, negative control) shows no interaction with them ( Figure S5D ). The binding molar ratio between apo-Tf and fibrinogen or AT-III is 4:1 or 2:1 ( Figure S5E respectively. The native gel shift assays also showed a complex formation between apo-Tf and thrombin ( Figure 3E ), FXIIa ( Figure 3F ), fibrinogen ( Figure 3G ) or AT-III ( Figure 3H ). SPR analysis also revealed that apo-Tf interacted with prothrombin and FXII ( Figures S5F and S5G) . substrates of thrombin have more spaces to access the triad residues. Similar to the Tf-thrombin complex, FXIIa interacts with Tf through its own groove-like domain (exosite I domain analogous), which is almost the same folding mode, and changes its conformation as the exosite I of thrombin does ( Figure S7 ).
Based on the docking model and the structural characteristics of the Tf-thrombin/FXIIa complex, we found that two key residues of Tf (E333 and E338) may play key roles in the interaction of Tf with thrombin/FXIIa. The mutant of Tf (E333R and E338R) was thus constructed ( Figures S8A-S8E) . Notably, the Tf mutant exhibited weak interaction with thrombin ( Figure 3I ) or FXIIa ( Figure 3K ). The ability of Tf mutant to potentiate thrombin ( Figure 3J ) or FXIIa ( Figure 3L ) was significantly decreased by comparison with wild-type Tf. Furthermore, the docking model also suggested two key residues of thrombin (R117 and R122) play a key role in the interaction of thrombin with Tf. The corresponding mutant (R117A and R122A) of thrombin ( Figures S8F-S8H ) exhibited significant weak interaction with Tf compared with wildtype thrombin ( Figure 3M ). Although the enzymatic activity of the thrombin mutant was not influenced, the ability of Tf to potentiate the thrombin mutant was significantly decreased ( Figure 3N ).
Given that Tf potentiates thrombin and FXIIa by interacting with them, we hypothesize that specific peptides at the binding site of thrombin or FXIIa may competitively bind to the same target in Tf and thus inhibit the effects of it on thrombin and FXIIa. Exosite I motif-based inhibitor peptides TH16 (RIGKHSRTRYERNIEK) and FX18 (RRNHSCEPCQTLAVRSYR)
were designed. SPR analysis revealed the critical interaction for the binding specificity of Tf to TH16 ( Figure 3O ) and FX18 ( Figure 3Q respectively. However, the scrambled peptide of TH16 (TH16-scr, RKKGIRRYTERHSNIE) and FX18 (FX18-scr, SCPTHYSRQRCRNAVLER) showed no interaction with Tf. Functional study showed that both TH16 and FX18 inhibited the potentiating activity of Tf on thrombin ( Figure   3P ) and FXIIa ( Figure 3R ) in a dose-dependent manner. TH16 or FX18 alone showed no effect on the enzymatic activity of thrombin or FXIIa even the concentration up to 10 M. Moreover, the formation of Tf-prothrombin and Tf-FXII complexes was also observed in atherosclerotic plaque by western blot analysis after being cross-linked, and the amount of which was greater than that in normal controls ( Figures 4F-4H ).
Tf over-expression aggravates atherosclerotic lesion and hypercoagulability which are attenuated by Tf down-regulation
To elucidate the role of Tf in atherosclerotic lesion development, the effects of Tf overexpression and knockdown on the development of AS and hypercoagulability were evaluated.
The Tf expression levels were first validated by qRT-PCR and western blot ( Figure S9 ). After the viruses were injected, the Apoe -/-mice were fed with a HFD for 6 weeks to spark and study the development of AS and hypercoagulability. As illustrated in Figure 5A , an increase in plasma concentration of Tf was observed in Tf over-expressed Apoe (Table S3 ).
The role of Tf in promoting hypercoagulability was further investigated in mouse thrombosis model induced by FeCl 3 . As illustrated in Figure 5G , blood flow in the carotid artery was significantly decreased in Tf over-expressed mice, suggesting an increased thrombus formation. Inversely, blood flow was increased in the Tf knockdown mice, suggesting an inhibited thrombosis formation. Consequently, as illustrated in Figure 5H , a substantial increase
in plaque size in the aortic root was observed in Tf over-expressed Apoe -/-mice, while reduced lesion formation was found in Tf knockdown Apoe -/-mice. In addition, the Tf-and thrombin/ FXIIa-positive deposits ( Figure 5I ) were also observed in the atherosclerotic lesion of Apoe
mice. These findings demonstrate that Tf plays a key role in hypercoagulability and atherosclerotic lesion development.
Interference with Tf exerts anti-hypercoagulability and anti-AS effects
After a 6-week treatment with an anti-Tf antibody, a decrease in plasma concentration of Tf was observed ( Figure S10A ), which is accompanied with the relative decreased enzymatic activities of thrombin ( Figure S10B ) and FXIIa ( Figure S10C ) as well as prolonged APTT ( Figure S10D ), PT ( Figure S10E ) and tail-bleeding time ( Figure S10F ), indicating decreased hypercoagulability in Apoe -/-mice depleted of Tf. Consequently, an obvious decrease in plaque size was observed in anti-Tf antibody treated Apoe -/-mice ( Figure 6A ). Importantly, no statistically significant changes at iron metabolism indexes and erythrocyte indexes were observed after anti-Tf antibody treatment (Table S3 ).
As illustrated in Figures S10G and S10H, both of exosite I motif-based peptides TH16 and FX18, which only inhibited Tf's potentiating ability on thrombin and FXIIa without direct effect on the enzymes ( Figures 3P and 3R ), prolonged plasma recalcification time in a dose-dependent manner, suggesting that the coagulation was inhibited by the two peptides. The increase in plasma recalcification time may further contribute to an extended bleeding time in mice ( Figure   S10I ). The inhibitory effects of TH16 and FX18 on thrombosis formation were further demonstrated by an increased blood flow in the carotid artery in vivo ( Figure 6B ). Moreover, after treatment for 3 weeks, TH16 and FX18 significantly decreased atherosclerotic plaque size
in a dose-dependent manner, indicating their anti-AS effects ( Figure 6C ). Together, these data indicate that Tf drives development of atherosclerotic plaque and that interference with Tf might harbor valuable opportunities for AS prevention and treatment.
Discussion
A balance between clotting and bleeding is always maintained by complicated interactions between coagulation and anti-coagulation system in the body under normal physiology. The coagulation process is under the inhibitory control of several inhibitors that limit the clot formation, thus avoiding the thrombus propagation (Esmon, 2000; Palta et al., 2014) . Main natural inhibitor of coagulation enzymes in plasma is AT-III with a concentration of ~3 M.
Compared with AT-III, coagulation proteases' concentration (pM to nM) is much lower, suggesting that coagulation proteases' functions are completely blocked by AT-III in normal circulation. Pro-coagulant state is found in CHD plasma, i.e., AS, suggesting that coagulation balance was interrupted and AT-III's inactivation on coagulation proteases is inhibited, but the process is unknown. By using AS plasma in this study, we found enhanced enzymatic activity of thrombin and FXIIa in atherosclerotic plasma although total levels of prothrombin and FXII are not different from normal plasma (prothrombin ~2 M, FXII ~0.375 M) (Mari et al., 2008) , and thus the concentration of thrombin and FXIIa should be less than 2 and 0.375 M, respectively, which is less than AT-III's concentration of ~3 M. Considering that AT-III binds and inactivates coagulation enzymes in a ratio of 1:1, we inferred that another plasma factor may block AT-III to contribute enhanced enzymatic activity of thrombin and FXIIa and to induce pro-coagulant state in AS plasma. Indeed, we found elevated level of Tf in human atherosclerotic plasma, which is associated
with enhanced enzymatic activity of thrombin and FXIIa and pro-coagulant state ( Figures 1A-1D and Figures S1-S2 ). The concentration of Tf in CHD patients' plasma samples was 46% higher than that in controls (4.173 vs 2.865 mg/ml). Additionally, elevated Tf level was also observed in the plasma and atherosclerotic plaque of AS mice ( Figures 1F-1H ). Further study indicated that
Tf directly interacts with fibrinogen, thrombin, FXIIa and AT-III with different affinity to maintain coagulation balance. Tf's KD for thrombin, FXIIa, fibrinogen and AT-III is 7.7, 13.9, 29
and 524 nM, respectively ( Figures 3A-3D ). Tf showed ability to potentiate enzymatic activities of thrombin and FXIIa, the two key coagulation proteases. Tf exists in plasma in either holo-Tf or apo-Tf, and about 30% to 40% is present as holo-Tf (Clark, 2008; Haber et al., 2008; Stack et al., 2014) . We found both holo-and apo-Tf showed a similar ability to bind thrombin, FXIIa, fibrinogen and AT-III. They also showed similar activity to potentiate thrombin and FXIIa and to which will be demonstrated in the accompanying paper.
Methods
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Specimens of human atherosclerotic plaque and plasma
The Institutional Review Board of Kunming Institute of Zoology (KIZ) and the Yan'an Affiliated Hospital of Kunming Medical University approved this study (KIZ-YA-20150109).
All human specimens were collected with the informed consent of the patients prior to the study.
Human plasma of patients with CHD (n = 42) and healthy controls (n = 42) were collected from
Yan'an Affiliated Hospital of Kunming Medical University (Table S1 ). In total, 42 subjects with CHD who had angiographically-visible luminal narrowing were selected in the present study.
The patients with clinical features of angina pectoris were further diagnosed by coronary angiography. The 42 patients were matched with 42 healthy volunteers as a normal control group with angiographically normal coronary arteries, and no history of hypertension, diabetes mellitus, or hypercholesterolemia disease. Immediately following the blood drawing (1.5 % EDTA-Na 2 was utilized as an anticoagulant agent), plasma was obtained by centrifuging at 3000 rpm/min for 20 min at 4°C, and stored at -80°C after being sub-packed.
Atherosclerotic plaque specimens were obtained from coronary endarterectomy, and normal arteries were obtained from coronary artery bypass surgery (n = 12, age 30-80) (Table S2 ) from
Yan'an Affiliated Hospital of Kunming Medical University. Immediately following surgical removal, some specimens were minced and homogenized at 4°C for protein extraction, and further stored at -80°C after being sub-packed; some were fixed in 10% buffered formalin to prepare a frozen section; others were placed in RNAlater (R0901-500ML, Sigma, USA) for RNA extraction and stored at -80°C for further use.
Animals and ethics statement
All animal experiments were approved by the Animal Care and Use Committee at Kunming Animal Company (Beijing, China) and housed in a pathogen-free environment.
Chromogenic assays
Effects of plasma from CHD patients and healthy controls on proteases (kallikrein, FXIIa, FXIa, FVIIa and thrombin) involved in coagulation were tested using corresponding chromogenic substrates. The testing enzyme was incubated with the plasma (1 μl) in 60 μl Tris-HCl buffer (50 mM, pH 7.4) for 5 min, and a certain concentration of chromogenic substrate was then added as described below. Absorbance at 405 nm was monitored immediately, and the kinetic curve was recorded using an enzyme-labeled instrument (Epoch, BioTek, USA) for 30 min. Relative enzyme activity was obtained by calculating the velocity of enzymatic hydrolysis of its substrate. 
Purification and identification of Tf
Albumin and IgG were first removed using HiTrap Albumin and IgG depletion column (GE, Page | 18 USA). Plasma was diluted (1:1) by 20 mM Tris-HCl buffer containing 20 mM NaCl (pH 7.8) and then applied to a Resource Q column (17-1177-01, GE, USA) for purification in a fast protein liquid chromatography (FPLC) system (GE, USA). The column was pre-equilibrated with solvent A (20 mM Tris-HCl, pH 7.8), and the elution was performed with a linear gradient of 0-100% solvent B (20 mM Tris-HCl, 1 M NaCl, pH 7.8) over 100 min. The fraction containing potentiating ability on thrombin and FXIIa was subjected to a Mono Q column (17-5166-01, GE, USA) using the same elution system as above for further purification.
The purified thrombin/FXIIa potentiator (10 μg) was dissolved in 25 mM NH 4 HCO 3 buffer and reduced by 10 mM dithiothreitol (DTT) for 1 h at 37°C. The reduced sample was alkylated by 30 mM iodoacetamide dissolved in the same buffer for 30 min at room temperature in a dark place. The alkylation reaction was ended by adding additional DTT. The sample was treated with 1% trypsin (w/w) at 37°C overnight for mass spectrometry analysis. The matrix-assisted laser desorption ionization time-of-flight mass spectrometer (MALDI-TOF/TOF mass spectrometer, Autoflex speed, BrukerDaltonics, Germany) was employed for data acquisition according to the manufacturer's instruction. The MS and MS/MS spectra were collected and processed using the FlexControl, FlexAnalysis and BioTools software (BrukerDaltonics, Germany).
Tf measurement in human plasma and tissue specimens
The concentration of Tf in the plasma of CHD patients and healthy controls was determined using human Tf ELISA kit (EK12012-96T, Multi Sciences, China) according to the manufacturer's instruction. Amounts of Tf in plasma and plaque homogenates were also determined by western blot analysis. Briefly, plasma and tissue homogenates were first separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then 11019-RP02, Sino Biological Inc, China) was used in the immunoreactivity. To control for plasma loading and transfer, membranes were stained by Red Ponceau after transferring, or blotting for β-actin as a plaque homogenates loading control.
Effects of Tf on enzymatic activity of coagulation factors
Effects of apo-Tf or holo-Tf (Sigma, purity greater than 98%, no residual enzyme activity of FXIIa and thrombin) on proteases involved in coagulation (kallikrein, FXIIa, FXIa, FVIIa and thrombin) were tested using corresponding chromogenic substrates as described above. Human serum albumin (HSA, purity greater than 98%) was used as a control. The effect of Tf on thrombin to hydrolyze its natural substrate ( activation were assayed using corresponding chromogenic substrates and reaction system as described above.
Effect of Tf on thrombin/FXa-AT-III complexes formation in vitro
Briefly, Tf (2.5-10 μM), AT-III (2 μM, A2221-125UG, Sigma, USA) and thrombin (20 nM Page | 21
Effects of Tf on blood coagulation
Healthy human plasma was collected from the Kunming Blood Center. To test the effect of Tf on plasma recalcification time, 20 μl of plasma was incubated with human apo-or holo-Tf (0.2-5 μM) in 60 μl of HEPES buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) for 10 min at 37 C, and 60 μl of 25 mM CaCl 2 preheated at 37 C was then added. The clotting was monitored at 650 nm and clotting time was calculated by measuring the time to half maximal increase in absorbance.
Mouse AS model
Apoe -/-mice (female, 8 weeks old) were fed a high fat diet (HFD, 21% fat, 0.15% cholesterol) for 6 weeks to induce AS, and some other Apoe -/-mice were fed a normal diet (ND) as controls.
After the 6-week induction, the mice were sacrificed and the blood were collected for further plasma preparation (blood was obtained by mixing 1 volume trisodium citrate (0.13 M) with 9 volumes blood, the plasma was then obtained by centrifuging at 3000 rpm/min for 20 min at 4 °C). The aortic root was immediately fixed in 4% paraformaldehyde dissolved in PBS at 4 C overnight following surgical removal, and organs including liver, brain, spleen, muscle, kidney, stomach, and plaque were also collected and placed in RNAlater for RNA extraction or PBS (20 mM phosphate, pH 7.4, 100 mM NaCl) for protein extraction. The mouse aortic root specimens were cut into 8 μm sections using a freezing microtome (Thermo Scientific). Some sections of aortic root were stained by oil-red O to investigate atherosclerotic lesion, and some others were used for immunofluorescent assay as described below. Images of oil-red O staining were acquired by a dark field microscope (Life technologies), and the oil-red O stained plaque area was measured by Image J.
The RNA extraction and cDNA reverse transcription were performed by using RNA extraction kit (DP419, Tiangen, China) and reverse transcription kit (A5000, promega, USA)
Page | 22
according to the manufacturer's instructions, respectively. Tf expression was quantified by both qRT-PCR (forward primer (5'-3'): GGACGCCATGACTTTGGATG; reverse primer (5'-3'):
GCCATGACAGGCACTAGACC) and western blot. PCR was performed on the Bio-Rad CFX-96 Touch Real-Time Detection System. The concentration of Tf in mouse plasma was determined using mouse Tf ELISA kit (ab157724, Abcam, USA). Amount of Tf in plaque homogenates was also determined by western blot analysis using the anti-Tf antibody (1:2000, 11019-RP01, Sino Biological Inc, China) as described above.
Surface plasmon resonance (SPR) analysis
BIAcore 2000 
Confocal microscopy
Human atherosclerotic plaque or mouse aortic root specimens were first cut into 8 μm sections antibody at 4 C overnight, respectively. After washing three times by PBS to remove excess primary antibody, the section was incubated with a fluorescently labeled secondary antibody for 1 h at 37 C. Cell nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI, Cat# P36941, Lifetechnologies, USA). Images of immunofluorescence were obtained by an Olympus
FluoView 1000 confocal microscope according to manufacture's instructions.
APTT and PT assays
For APTT assay, 50 μl of APTT reagent (F008-1, Nanjing Jiancheng Bioengineering Institute,
China) was incubated with 50 μl plasma for 3 min at 37°C, and then 50 μl of CaCl 2 (25 mM) preheated at 37°C was added to test the clotting time by monitoring the absorbance at 405 nm using a semi-automatic coagulation analyzer (ThromboScreen 400c, pacific hemostasis, USA).
To test PT, 50 μl plasma preheated at 37°C was mixed with 100 μl PT reagent (F007, Nanjing
Jiancheng Bioengineering Institute, China) preheated at 37°C for 15 min by monitoring the absorbance at 405 nm.
Bleeding time measurement
Mouse tail transection model was used to test the tail-bleeding time. In brief, mice tail was cut 2 mm from the tip, and then carefully immersed in 20 ml of saline warmed at 37°C. The bleeding time was recorded until the stream of blood ceased. were assayed using a blood routine test machine (BC-2800Vet, Mindray, China).
Molecular docking and inhibitory peptides designing
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FeCl 3 -induced carotid artery thrombus formation
The C57BL/6J mice (female, 8 weeks old) or Apoe -/-mice (female, 8 weeks old) with Tf interference were first anaesthetized with 2.0% isoflurane and core body temperature was maintained at 37 C during the whole surgery. One of the carotid arteries was exposed by cervical incision, and separated from the adherent tissue and vagus nerve. Thrombosis was induced by applying a piece (2 × 2 mm) of filter paper that was pre-soaked with 10% (w/v) FeCl 3 solution to the exposed mice carotid artery. The blood flow of the carotid artery of all groups was measured by laser speckle perfusion imaging (PeriCam PSI, HR, Sweden) at 5 min and 10 min after FeCl 3 induction, respectively. The perfusion unit of region of interest (ROI) was also recorded to quantify the blood flow changes.
Statistical analysis
The data obtained from independent experiments are presented as the mean ± SD. All statistical analyses were two-tailed and with 95% confidence intervals (CI). The results were analyzed using one-way ANOVA with Dunnett's post hoc test or unpaired t-test by Prism 6 (Graphpad Software) and SPSS (SPSS Inc, USA). Differences were considered significant at p < 0.05. 
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